News Daily News Lp(a) Levels Linked to Aortic Valve Calcification, Not Progression Michael O'Riordan August 08, 2022
News Daily News Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy Todd Neale July 20, 2022
News Conference News EAS 2022 FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses Michael O'Riordan May 26, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Daily News Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV Michael O'Riordan May 09, 2022
News Daily News Pelacarsen Targets Lp(a), With Little Impact on LDL Cholesterol Michael O'Riordan March 15, 2022
News Daily News Recurrent Stroke Risk Lower With More Intense LDL-Lowering: Meta-analysis Yael L. Maxwell March 01, 2022
News Daily News Absence of CAC May be Protective Even in Patients With Very High Cholesterol Michael O'Riordan February 14, 2022
News Daily News Homozygous FH Diagnosis Often Comes Late, With Lackluster Care Michael O'Riordan February 10, 2022
News Features Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path Michael O'Riordan January 17, 2022
News Daily News Upping Generic CV Drug Scripts Could Save Medicare and Patients Millions L.A. McKeown December 17, 2021
News Daily News British Medical Groups Express Concern About Inclisiran Rollout Michael O'Riordan December 14, 2021
News Conference News AHA 2021 ApoB Gains Ground as Best Lipid Predictor of MI Risk Michael O'Riordan November 22, 2021
News Conference News AHA 2021 Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients Michael O'Riordan November 13, 2021
News Daily News Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT Michael O'Riordan October 04, 2021
News Daily News Heterozygous FH Diagnosed Late, Remains Undertreated Michael O'Riordan September 13, 2021
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER Michael O'Riordan September 02, 2021
News Conference News ESC 2021 Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD Michael O'Riordan August 29, 2021